omapatrilat


Also found in: Wikipedia.

omapatrilat

Cardiology A vasopeptidase inhibitor that inhibits neural endopeptidase and ACE, used to manage HTN. See Isolated systolic hypertension, OPERA, Vasopeptidase inhibitor.
References in periodicals archive ?
VPIs were single-molecular entities, with omapatrilat as the most advanced of those that inhibited NEP and ACE.
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial.
The investigational drug omapatrilat (Vanlev), which combined inhibition of both ACE and NEP, appeared to be a powerhouse, beating such leading agents as losartan and amlodipine.
This analysis used data collected in a 25,000-patient study that compared the drugs omapatrilat and enalapril in patients with hypertension.
A combined analysis of two Phase II studies comparing a new cardiovascular drug called omapatrilat with an ACE inhibitor called lisinopril shows that the new treatment appears to be more effective in preventing death or hospitalization in patients diagnosed with congestive heart failure.
Rekombinant DNA teknigi ile uretilen BNP analogu nesiritidin kalp hizinda ve oksijen tuketiminde artisa yol acmadan pulmoner tikali basincta azalmaya ve genel bir semptomatik iyilesmeye neden olmasi, dusuk doz subkutan BNP'nin notral endopeptidaz (NEP) omapatrilat ile kombine edildiginde kalp debisinde artma, ventrikul dolus basincinda azalma gibi kalp uzerine yararli etkilerinin gorulmesi uzerine dekompanse kalp yetersizliginde intravenoz insan kaynakli BNP uygulanmasi FDA onayi almis (4) olmasinin yani sira, peptidlerin enzimatik yikima ugramasi nedeniyle kronik tedavi amacli kullanimi sinirlidir.
Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
BERLIN -- The investigational vasopeptidase inhibitor omapatrilat is consistently more effective than ACE inhibitor therapy at lowering blood pressure in difficult-to-control hypertensive patients at high mortality risk as evidenced by prior major cardiovascular events or diabetes.
In the high-risk subgroup, omapatrilat consistently lowered systolic blood pressure by 34 mm Hg more than enalapril, a difference maintained even when doses were titrated upward or other drugs were added, Dr.
Omapatrilat, a promising drug for hypertension and heart failure that was on track for Food and Drug Administration approval this summer, has hit a regulatory snag.
The risk of serious angioedema persuaded the majority of a federal advisory panel to recommend against approving omapatrilat, despite an antihypertensive effect that has been found in trials to exceed that of other available antihypertensive drugs.
ATLANTA -- Omapatrilat, a drug from a new class of cardiovascular agents, showed unprecedented activity in reducing systolic blood pressure in phase III trials.